Morningstar

Delphi Diagnostics® Announces Four Abstracts and one General Session Presentation Featuring the Endocrine Activity Index™ to be Presented at the San Antonio Breast Cancer ...

GS3-05: Evaluation of the Sensitivity to Endocrine Therapy (SETER/PR) assay to predict benefit from extended endocrine therapy in the NRG/NSABP B-42 trial Author: Eleftherios P Mamounas, AdventHealth ...
Morningstar

New Data Confirms Endocrine Activity Index® as a Predictor of Benefit from Dose-Dense Chemotherapy

HOUSTON, March 5, 2025 /PRNewswire/ -- Delphi Diagnostics, Inc. announces two important pieces of evidence to support the Endocrine Activity Index as a predictor of benefit from Dose-Intense ...
abc27

Delphi Diagnostics® Announces Four Abstracts and one General Session Presentation Featuring the Endocrine Activity Index™ to be Presented at the San Antonio Breast Cancer ...

HOUSTON, Nov. 4, 2025 /PRNewswire/ -- Delphi Diagnostics announces the upcoming presentation of four scientific abstracts, including one platform presentation highlighting new clinical data supporting ...